Feature | July 27, 2010| Mariell Jessup, M.D., professor of medicine, University of Pennsylvania School of Medicine

Novel Therapies for Advanced Heart Failure

New approaches include mechanical heart pumps, drug and gene therapies

Mariell Jessup, M.D., is a professor of medicine at the University of Pennsylvania School of Medicine.

Heart failure is a progressively debilitating disease that dramatically decreases the life expectancy and quality of life of affected patients. Nearly 5.8 million Americans are diagnosed with heart failure today, according to annual American Heart Association statistics. Heart failure contributes to more than 280,000 deaths annually, with a one-year mortality rate of approximately 20 percent, and a five-year mortality estimated at 50 percent.

Heart failure accounts for nearly 20 percent of total hospital admissions; annual hospitalizations with a primary diagnosis of heart failure in the U.S. exceed 1 million. The incidence of heart failure has not declined within the past 20 years, but the survival after onset has increased in younger patients and men. The care of patients with heart failure will lead to $39.2 billion direct and indirect costs to the United States in 2010.

Heart Failure Characteristics

Heart failure is characterized by chronic, persistent activation of the renin-angiotensin-aldosterone system as well as the sympathetic nervous system. The neurohormonal blockade of these systems has been the mainstay of heart failure therapy for more than 20 years. The implementation of angiotensin-converting enzyme (ACE) inhibitors and antiandrenergic therapies has revolutionized the treatment of heart failure to slow the progression of heart failure and improve survival. The current regimen for managing heart failure includes ACE-inhibitors, angiotensin-receptor antagonists, beta-blockers, aldosterone antagonists and diuretics; certain patients are candidates for a special pacemaker called cardiac resynchronization therapy (CRT) and others undergo coronary bypass surgery.

Pumps and Transplants

Nevertheless, heart failure is a progressive disease with no cure. As the disease progresses, existing treatment options for advanced heart failure are limited to left ventricular assist device implantation (LVAD) or cardiac transplant. Patients who have severe heart failure and primary myocardial disease, ischemic cardiomyopathy, or congenital heart disease may be considered for cardiac transplantation, but only approximately 2,000 heart transplants are done each year in the United States. Moreover, many patients depend on mechanical cardiac support devices while waiting for a transplant donor organ to become available. Additionally, many patients with end-stage heart failure are not considered for transplantation because of advanced age or other associated morbidities.

Drug and Gene Therapies

Therefore, there is a significant unmet need for novel approaches beyond the standard medical regimens currently used to treat advanced heart failure patients. The majority of current clinical studies are investigations with new approaches to reduce the mortality in acute heart failure, e.g. patient admitted to the hospital with exacerbated symptoms of heart failure. One eagerly awaited trial is the ASCEND-HF study (Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure), which enrolled 7,000 patients worldwide and is designed to evaluate whether treatment with nesiritide improves patient outcomes or heart failure symptoms compared with placebo.

Another novel approach to treat heart failure has been to target the up-regulation of sarcoplasmic reticulum (SR) Ca2+ ATPase pump (SERCA2a). SERCA2a is critical in controlling the movement of Ca2+ between the SR and cytoplasm; it regulates Ca2+ cycling and contractility in the myocardium. SERCA2a expression is significantly reduced in failing hearts, leading to abnormal Ca2+ handling and deficient contractility, a defect that could be corrected by restoring SERCA2a levels. Additionally, in animal models, cardiac energetics and electrical remodeling improved after SERCA2a gene transfer.

The first-in-human trial to utilize this novel gene therapy, CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) was recently presented in Berlin. It is noteworthy that the procedure to infuse Mydicar, a genetically targeted enzyme replacement therapy that restores SERCA2a levels via gene transfer with a recombinant adeno-associated vector (AAV), could be performed in an outpatient setting. The results showed significant improvements in clinical outcomes and symptoms in patients with advanced heart failure treated with Mydicar. These patients significantly improved their heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function. These encouraging results will have to be confirmed in larger clinical trials but may address the unmet need for novel therapeutic approaches to treat advanced heart failure.

Related Content

St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
coronary CT angiography, CCTA, alcohol consumption, CAD, coronary artery disease, RSNA 2016
News | CT Angiography (CTA)| November 29, 2016
Researchers using coronary computed tomography angiography (CCTA) found no association between light to moderate...
News | Cath Lab| November 21, 2016
November 21, 2016 – A single-center study sponsored by the National Institutes of Health (NHLBI) failed to show an ea
InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid| November 18, 2016
November 18, 2016 — InspireMD Inc.
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
cardiac rehabilitation, depression, death risk, heart surgery, Intermountain Medical Center Heart Institute, AHA Scientific Sessions 2016
News | Cardiac Rehabilitation| November 15, 2016
Depression has been known to be associated with poor cardiovascular outcomes. But if patients who are depressed attend...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
Medtronic, Claria MRI Quad CRT-D SureScan, FDA approval
Technology | Cardiac Resynchronization Therapy Devices (CRT)| November 15, 2016
Medtronic plc  has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac...
Overlay Init